Drug Safety

Gout Cavalcade (7.10.2026)

Save

Dr. Jack Cush reviews the news, journal articles and regulatory decisions from the past week. July is Gout: More than Flares month.

Do we need Better Strategies to Prevent Osteoporotic Fractures?

Save

In a recent JAMA Viewpoints article, Dr. Susan Ott addresses several controversies in preventing osteoporosis (OP) related fractures.

FDA Delays Gout Drug NASP with Complete Response Letter

Save

At the end of June, Sobi was awaiting an FDA decision on its Biologics License Application (BLA) for NASP (nanoencapsulated sirolimus plus pegadricase) for the treatment of adult patients with uncontrolled gout. On June 26, 2026, SOBI received a Complete Response Letter from the U.S. FDA that

NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan

Save

The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil

DMARD Efficacy in RA-ILD

Save

A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional, low-certainty recommendations.

ICYMI: Updated CRA/SPARCC Recommendations for Axial Spondyloarthritis

Save

In 2024, the Canadian Rheumatology Association (CMA) and the Spondyloarthritis Research Consortium of Canada (SPARCC) published a comprehensive set of 56 treatment recommendations for the management of axial spondyloarthritis. This first update is focused on the reassessment of IL-17i

EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA

Save

EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids.

ICYMI: Worldwide Trends in Hyperuricemia

Save

A Lancet Rheumatology systematic review shows the prevalence of hyperuricaemia has risen markedly over the past two decades in both men and women, owing to population growth, aging, and increasing age-specific rates

EULAR26: GLP-1 Agonist Use in the RISE Registry

Save

At EULAR 2026, McCormick and Curtis et al presented data from the American College of Rheumatology’s (ACR) Rheumatology Informatics System for Effectiveness (RISE) registry on the use of GLP-1 agents in rheumatic diseases (RMD). 

ICYMI: VEXAS Syndrome - A Review

Save

Beck et al has published a review of the VEXAS syndrome in The Lancet, focusing on the pathogenesis, spectrum, and treatment strategies.

ICYMI: Glucocorticoid Injections in Knee Osteoarthritis

Save

A randomized clinical trial of 60 patients found that glucocorticoid injections into the infrapatellar fat pad (IPFP) did not significantly reduce pain scores in patients with inflammatory knee osteoarthritis (compared to placebo).

Spotlight on Comorbidities from EULAR 2026

Save

Systemic autoimmune diseases are associated with increased cardiovascular morbidity and mortality – possibly through autonomic imbalance, myocardial inflammation, or fibrotic infiltration of the conduction system. A team in Colombia have been looking into the

ICYMI: 2025 Update: EULAR Recommendations on Rheumatoid Arthritis Management

Save

The European Alliance of Associations for Rheumatology (EULAR) has updated their rheumatoid arthritis (RA) management recommendations, notably with fewer recommendations (total of 9, down from 11 in 2022 version), by merging and removing previous recommendations.

ICYMI: B Cells at the Brink in Sjögren Disease

Save

A recent issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder.

Generic Tofacitinib (6.26.2026)

Save

Dr. Jack Cush reviews the news and journal articles from RheumNow.com. Updates on tofacitinib, CAR-T therapy and AI.

EULAR26: Pitfalls in Treat-to-Target

Save

Real-world or observational data from registries, claims datasets, or electronic health records can enable us to perform large-scale analyses. These findings complement the insights gained from randomised trials, and can help to improve patient care and outcomes.¹ As a key example

B cell Targeting in SLE

Save

Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.

No Fetal Risks with First Trimester NSAID Use

Save

PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital malformatoin (MCM) risk. 

Pain management during pregnancy

JAMA Review on Low Back Pain

Save

A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain, drawing on 108 publications identified from a PubMed search (2005–2026) and the most recent guidelines from the WHO, ACP, and NICE.

Do You Zoster Vaccinate? (6.19.2026)

Save

Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026.